Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)
Open Access
- 5 November 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (2), 171-176
- https://doi.org/10.1002/ajh.25343
Abstract
β‐thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β‐globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as non‐transfusion‐dependent thalassemia (NTDT) or transfusion‐dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient‐reported outcomes (PRO), including health‐related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease‐specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)‐compliant PRO of chronic anemia symptoms, the NTDT‐PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18‐47) and 60% were female. The initial development of the NTDT‐PRO tool involved concept‐elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT‐PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT‐PRO. The final NTDT‐PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT‐PRO is a new disease‐specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.Keywords
Funding Information
- Celgene
This publication has 8 references indexed in Scilit:
- Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative StudyBlood, 2016
- Morbidities in non‐transfusion‐dependent thalassemiaAnnals of the New York Academy of Sciences, 2016
- Validation and reliability of a disease‐specific quality of life measure (the TranQol) in adults and children with thalassaemia majorBritish Journal of Haematology, 2013
- Non-transfusion-dependent thalassemiasHaematologica, 2013
- Ineffective Erythropoiesis inβ-ThalassemiaThe Scientific World Journal, 2013
- Psychometric properties of the Specific Thalassemia Quality of Life Instrument for adultsPatient Preference and Adherence, 2012
- Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO InstrumentValue in Health, 2011
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 2006